Chronic total occlusion: Does anti-platelet choice impact outcomes?

Key Points

• Chronic total occlusion (CTO) is associated with worse outcomes compared to non CTO percutaneous coronary intervention (PCI).
• CTO might be associated with vasomotor dysfunction
• Ticagrelor is a novel P2Y12 inhibitor that increases local adenosine
• The TIGER-BVS trial plans to assess the impact of using ticagrelor vs. clopidogrel on vasomotor activity and outcomes after successful CTO PCI.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2mjrrXN
via IFTTT